Ravulizumab to prevent delayed graft function after kidney transplant
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study tests an investigational medicine (ravulizumab) given through a vein to see if it can prevent delayed graft function—meaning the new kidney takes longer to start working—after a high-risk kidney transplant. It is for adults on dialysis who are getting a kidney from a donor whose heart stopped or who is considered high-risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have end-stage kidney disease and are on dialysis.
- You are waiting for a kidney from a donor whose heart stopped (DCD) or from a high-risk brain-dead donor.
- The donor must not be from certain high-risk categories (like sudden cardiac death outside hospital).
- The donor cannot have severe acute kidney injury at the time of donation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medicine called vonoprazan fumarate can help prevent delayed kidney function after a first kidney transplant from a deceased donor. It is for people who are ready to follow standard post-transplant care.
This study tests a drug called ravulizumab for children aged 2 to under 18 with IgA nephropathy, a kidney condition. It aims to see if the drug can help protect the kidneys and reduce protein in the urine.
This trial tests an immune-suppressing medicine to stop a serious complication called primary graft dysfunction that can happen soon after a lung transplant. It may help people who are already on the transplant waiting list and plan to receive a standard anti-rejection drug regimen.
This trial tests a new medicine called imlifidase that quickly removes harmful antibodies from the blood. It is given to children before a kidney transplant to make the donated kidney more likely to be accepted, especially when standard desensitisation methods have failed.
This trial tests whether starting ruxolitinib early, guided by a blood marker, can prevent acute graft-versus-host disease (aGVHD) after a stem cell transplant. It's for people who have already had a transplant and are at risk for this complication.
This trial tests the drug ravulizumab for people with aHUS (a rare blood and kidney condition). It aims to see if the drug can help improve blood counts and kidney function.
Hear when a new Delayed Graft Function trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.